Events|

SHL at the 2016 Prefilled Syringes Seminar Tokyo

News Page Homepage 800x480

SHL is glad to announce that it is going to participate in the Prefilled Syringe Seminar 2016 Tokyo, organized by PDA Japan Chapter. The seminar will take place at Sola City Conference Center on May 17-18, 2016.

This year, SHL is going to speak about the requirements on prefillable containers for the perfect fit into devices. The issue is important and widely discussed in the pharmaceutical and manufacturing industries and SHL is proud to make its contribution to the debate.

In addition to being a speaker at the seminar, SHL will also participate in the exhibition accompanying it. The spotlight will be on our two latest products – Molly® 2.25 and Molly® C.

Molly® 2.25 is our large-volume autoinjector based on the Molly® preconfigured program. Mike Weng, Executive Director of Business Development for Asia comments: “We are very proud to bring Molly® 2.25 to Japan. As our first large-volume autoinjector, Molly® 2.25 creates the long-needed bridge between larger volume primary containers and drug delivery.”

SHL’s most recent and most innovative product – Molly® C – is a connected autoinjector that transmits injection data to the user’s mobile device. It was developed as a part of our connectivity-dedicated program Alubena® to showcase the benefits and prospects of connected products.

Molly® 2.25, Molly® C and other SHL products will be available for demonstration at the exhibition. The exhibition will take place parallel to the seminar in the East Room of Sola City Conference Center on the 2nd floor.

About SHL

SHL Group is a world-leading solution provider in the design, development and manufacturing of advanced drug delivery devices such as autoinjectors, pen injectors and advanced inhaler systems. We also offer core competencies and services in the fields of medtech and patient care solutions. With locations in Taiwan, Switzerland, Sweden, China and the US, our experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.

With over 4,800 employees worldwide, SHL Group consists of several distinct group companies:

SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe.

SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use.

SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products.

For additional information, visit www.shl.group

 

Share:

Related News